~~<i id='8F75C1C204'><strike id='8F75C1C204'><tt id='8F75C1C204'><pre id='8F75C1C204'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

Wikipedia

author：comprehensive 2025-09-29 18:18:39 - browse：14

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Why health records don't always know when patients are dead

Wikipedia

knowledge

focus

entertainment

focus

SilasBuchanan,CEOofOurHealthyCommunity,speaksonapanelaboutdemocratizingclinicaltrialsattheMilkenInst

WSS

Christmas in the PICU brings some surprising joy

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Medicare Advantage beneficiaries sue Humana over algorithm use

Medicare drug price negotiation hasn't dried up venture capital

UnitedHealth financials solid despite Change Healthcare cyberattack

FTC falls short on scrutinizing hospital mergers, study says

knowledge

Wikipedia

Wikipedia

Dobbs anniversary: the lost opportunity of abortion as health care

Hospitals owned by private equity see complications spike 25%

What does generative AI mean for health care? We asked experts

What STAT readers think about the FDA and patient advocacy

New air purifier tech could be key to improving indoor air quality

SNAP should offer more nutrition education

Heart attack and stroke risk calculators need revising

Three trends to watch in biotech in 2024

The cancer drug shortage isn’t new — and neither are the solutions

Health care needs a new profession: neuroimaging counseling

knowledge

FTC falls short on scrutinizing hospital mergers, study says

Cancer researcher Catriona Jamieson is sending tumors into space

Virtual care provider acquires bankrupt Pear's prescription apps

What STAT readers think about the FDA and patient advocacy

Christmas in the PICU brings some surprising joy

SEC charges former device maker CEO with $41 million fraud

focus

focus

entertainment

focus